Overmedication is not a fringe concern — it's a common preventable harm in American healthcare. Adverse drug events (ADEs) send more than 1.5 million people to U.S. emergency departments every year. [1] The CDC defines an ADE as harm caused by a medication, including allergic reactions, side effects, medication errors, and overmedication itself. [1]
The problem compounds with the number of medications a patient is taking. Polypharmacy, generally defined as five or more medications daily, affects 37% of the general population and 65% of adults over 65. [2] In long-term care settings, the burden climbs further: one analysis found that up to 74% of patients in skilled nursing facilities take nine or more medications. [3] A widely cited rule of thumb holds that patients taking five medications will, on average, experience at least one significant drug-related problem. [3]
Fixed-dose combination products and standard weight-based protocols are convenient, but literature shows that uniform dosing does not fit every patient equally well. [7] Because metabolism, body composition, and comorbidities vary widely, a dose calibrated for an average patient can be too high for some and too low for others, increasing the risk of side effects without necessarily improving efficacy.
The evidence for individualized titration is strong. In a growth hormone study, patients who received individualized dose titration achieved similar efficacy to those on a fixed weight-based protocol, but experienced side effects at a rate of only 30%, compared with 70% in the fixed-dose group. [8] Titration guidance embedded in clinical protocols has likewise been shown to reduce the incidence of adverse drug reactions, [9] and current ADHD treatment guidelines recommend individualized dose optimization over one-size-fits-all fixed dosing. [10]
Individualized titration achieved similar efficacy to fixed weight-based dosing — with side effects in 30% of patients, compared with 70% on the fixed-dose protocol.
Not every Trifluent product addresses this gap the same way — and that's by design. Trifluent's portfolio takes several distinct approaches to the dosing and adherence challenges outlined above, matched to what each therapy and patient population actually needs.
Dicyclomine 40 mg is the only FDA-approved 40 mg dicyclomine on the market, letting prescribers reach an effective dose in a single tablet rather than multiple lower-strength doses — directly reducing pill burden for the patient.
Products such as an econazole nitrate topical foam and a lactulose for oral solution packaged in single-dose packets address adherence and convenience through delivery format, independent of dose titration.
For select therapies — such as fenofibrate, offered in both 40 mg and 120 mg strengths — Trifluent provides a broader range of dosing increments specifically so prescribers can titrate therapy to a patient's response, tolerability, and clinical profile.
The goal across all three approaches is the same: fewer patients over- or under-dosed, or burdened with more pills than necessary, simply because the available product didn't match what they actually needed. Which approach applies depends on the therapy — dose consolidation where fewer, stronger doses reduce burden; alternative formulations where delivery format matters more than titration; and true flex dosing, in products where it's offered, where a broader strength range supports individualized titration.
Want to see Flex Dosing in action? Join us for a Lunch & Learn — a working session with Trifluent's clinical team covering dosing strategies and how Flex Dosing fits into a busy prescribing practice. Lunch is on us.
Prefer to talk one-on-one first? Contact a Trifluent representative instead.
This content is intended for healthcare professionals. It is educational in nature and does not constitute clinical guidance for any individual patient. Prescribing decisions should always be based on full product labeling and individual patient assessment.
At Trifluent Pharma, our focus is on quality, consistency, and accessibility, ensuring essential medications reach the people who need them most.
